These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [TBL] [Abstract][Full Text] [Related]
44. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series. Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164 [TBL] [Abstract][Full Text] [Related]
45. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks. Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288 [TBL] [Abstract][Full Text] [Related]
46. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization. Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271 [TBL] [Abstract][Full Text] [Related]
53. Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up. Chen CH; Wu PC; Chen YJ; Liu YC; Kuo HK J Ocul Pharmacol Ther; 2011 Aug; 27(4):395-400. PubMed ID: 21770740 [TBL] [Abstract][Full Text] [Related]
54. Combined therapy: photodynamic therapy and bevacizumab to treat myopic neovascular membranes. One-year follow-up. Desco MC; Mataix J; Garcia-Pous M; Palacios-Pozo E; Navea A Retina; 2011 Mar; 31(3):475-81. PubMed ID: 20966825 [TBL] [Abstract][Full Text] [Related]
55. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966 [TBL] [Abstract][Full Text] [Related]
56. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Arevalo JF; Adan A; Berrocal MH; Espinoza JV; Maia M; Wu L; Roca JA; Quiroz-Mercado H; Ruiz-Moreno JM; Serrano MA; Retina; 2011 Feb; 31(2):353-63. PubMed ID: 20890239 [TBL] [Abstract][Full Text] [Related]
57. Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study. Pasyechnikova NV; Naumenko VO; Korol AR; Zadorozhnyy OS; Kustryn TB; Henrich PB Ophthalmologica; 2015; 233(1):2-7. PubMed ID: 25501802 [TBL] [Abstract][Full Text] [Related]
58. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION. Wu TT; Kung YH Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318 [TBL] [Abstract][Full Text] [Related]
59. CORRESPONDENCE OF LEAKAGE ON FLUORESCEIN ANGIOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY PARAMETERS IN DIAGNOSIS AND MONITORING OF MYOPIC CHOROIDAL NEOVASCULARIZATION TREATED WITH BEVACIZUMAB. Battaglia Parodi M; Iacono P; Bandello F Retina; 2016 Jan; 36(1):104-9. PubMed ID: 26166803 [TBL] [Abstract][Full Text] [Related]
60. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Lai TY; Chan WM; Liu DT; Lam DS Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]